文献速递青光眼

凝胶支架与小梁切除术:随机、多中心、金标准通路研究(GPS)12个月有效性与安全性比较

Gel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months.
PubMed 文献 · Am J Ophthalmol · 2023-03-25

这项前瞻性随机多中心非劣效研究将开角型青光眼患者按2:1随机分配至凝胶支架植入或小梁切除术,12个月时凝胶支架在主要终点(≥20%眼压下降且无用药增加、临床低眼压、视力降至数指或再次手术)上达到非劣效;小梁切除术平均眼压更低,凝胶支架术后干预更少、视力恢复更快且不良事件更少。

要点

  • 12个月时凝胶支架组62.1%、小梁切除术组68.2%达到主要终点,组间差-6.1%(95%CI -22.9%, 10.8%),达非劣效。
  • 小梁切除术平均眼压降低更明显,眼压变化组间差2.8 mm Hg(P=.024)。
  • 凝胶支架组需诊室术后干预的眼更少(排除激光缝线松解后P=.024),视力恢复更快(P≤.048)。

核心结论

  • 12个月时,按达到≥20%眼压下降且无用药增加、无临床低眼压、无视力降至数指、无再次手术的患者百分比,凝胶支架统计学非劣效于小梁切除术。
  • 小梁切除术获得统计学更低的平均眼压、数值上更低的失败率和数值上更低的补充用药需求。
  • 凝胶支架术后干预更少、视力恢复更好且不良事件更少。

研究设计与样本

  • 前瞻性、随机、多中心、非劣效研究。
  • 纳入眼压15至44 mm Hg且正在使用降眼压滴眼液的开角型青光眼患者,按2:1随机分配至凝胶支架植入或小梁切除术。
  • 主要终点为第12个月达到≥20%眼压下降且无用药增加、无临床低眼压、无视力降至数指、无再次手术的患者百分比,非劣效界值24%。

主要发现

  • 第12个月凝胶支架组62.1%、小梁切除术组68.2%达到主要终点(P=.487),组间差-6.1%(95%CI -22.9%, 10.8%)。
  • 两组平均眼压和用药数较基线下降均显著(P<.001);眼压变化组间差2.8 mm Hg,利于小梁切除术(P=.024)。
  • 凝胶支架组需诊室术后干预的眼更少(排除激光缝线松解后P=.024),视力恢复更快(P≤.048),6个月时视觉功能问题(患者报告结局)改善更大(P≤.022)。
  • 最常见不良事件为任何时间视力下降(凝胶支架38.9%,小梁切除术54.5%)和低眼压(任何时间眼压<6 mm Hg;凝胶支架23.2%,小梁切除术50.0%)。

关键数值与推荐

  • 主要终点非劣效界值为24%,凝胶支架组与小梁切除术组组间差-6.1%(95%CI -22.9%, 10.8%),达到非劣效。
  • 第12个月主要终点达标率:凝胶支架组62.1% vs 小梁切除术组68.2%(P=.487)。
  • 眼压变化组间差2.8 mm Hg,利于小梁切除术(P=.024)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare effectiveness and safety of the gel stent to trabeculectomy in open-angle glaucoma (OAG). DESIGN: Prospective, randomized, multicenter, noninferiority study. METHODS: Patients with OAG and intraocular pressure (IOP) 15 to 44 mm Hg on topical IOP-lowering medication were randomized 2:1 to gel stent implantation or trabeculectomy. Primary end point (surgical success): percentage of patients at month 12 achieving ≥20% IOP reduction from baseline without medication increase, clinical hypotony, vision loss to counting fingers, or secondary surgical intervention (SSI) in a noninferiority test with 24% margins. Secondary end points (month 12) included mean IOP and medication count, postoperative intervention rate, visual recovery, and patient-reported outcomes (PROs). Safety end points included adverse events (AEs). RESULTS: At month 12, the gel stent was statistically noninferior to trabeculectomy (between-treatment difference [Δ], -6.1%; 95% CI, -22.9%, 10.8%); 62.1% and 68.2% achieved the primary end point, respectively (P=.487); mean IOP and medication count reductions from baseline were significant (P<.001); and the IOP change-related Δ (2.8 mm Hg) favored trabeculectomy (P=.024). The gel stent resulted in fewer eyes requiring in-office postoperative interventions (P=.024 after excluding laser suture lysis), faster visual recovery (P≤.048), and greater 6-month improvements in visual function problems (ie, PROs; P≤.022). The most common AEs were reduced visual acuity at any time (gel stent, 38.9%; trabeculectomy, 54.5%) and hypotony (IOP <6 mm Hg at any time) (gel stent, 23.2%; trabeculectomy, 50.0%). CONCLUSIONS: At month 12, the gel stent was statistically noninferior to trabeculectomy, per the percentage of patients achieving ≥20% IOP reduction from baseline without medication increase, clinical hypotony, vision loss to counting fingers, or SSI. Trabeculectomy achieved a statistically lower mean IOP, numerically lower failure rate, and numerically lower need for supplemental medications. The gel stent resulted in fewer postoperative interventions, better visual recovery, and fewer AEs.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sheybani A, Vera V, Grover DS, et al. Gel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months. Am J Ophthalmol. 2023. PMID: 36972738. doi:10.1016/j.ajo.2023.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。